AL SAFETY DATA SHEET Date-Issued: 05/07/2012 MSDS Ref. No: 074 Date-Revised: 05/04/2012 Revision No: 3 1. PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME: VAP-5 PRODUCT DESCRIPTION: Liquid Insecticide PRODUCT CODE: #71 EPA REG. NO. : 47000-71 MANUFACTURER 24 HR. EMERGENCY TELEPHONE NUMBERS CHEMTREC U.S. and CANADA:(800) 424-9300 CHEMTREC All Other Areas:(703) 527-3887
For information regarding MEDICAL EMERGENCIES or PESTICIDE INCIDENTS, call the INTERNATIONAL POISON
2. COMPOSITION / INFORMATION ON INGREDIENTS Chemical Name
Dichlorvos (DDVP) Dimethyl 2,2-diclorovinylphosphate
COMMENTS: Ingredients not identified are proprietary or non-hazardous. Values are not product specifications. 3. HAZARDS IDENTIFICATION EMERGENCY OVERVIEW IMMEDIATE CONCERNS: DANGER – POISON. Fatal if swallowed, inhaled or absorbed through skin and eyes. Rapidly
absorbed through skin. Do not get in eyes, on skin or on clothing. Do not breathe vapor or spray mist. Repeated inhalation or skin contact may, without symptoms, progressively increase susceptibility to Dichlorvos (DDVP) poisoning. Combustible. DO NOT use or store near heat, sparks, open flame, or any other ignition sources.
POTENTIAL HEALTH EFFECTS EYES: Eye irritant. SKIN ABSORPTION: May be fatal if absorbed through the skin. INGESTION or INHALATION: May be fatal if swallowed or inhaled. SIGNS OF ACUTE OVEREXPOSURE: Acute cholinesterase depression may be evidenced by headache, nausea, vomiting, diarrhea, abdominal cramps, excessive sweating, salivation and tearing, constricted pupils, blurred vision, tightness in chest, weakness, muscle twitching and confusion. In extreme cases, unconsciousness, convulsions, severe respiratory depression and death may occur. SIGNS OF CHRONIC OVEREXPOSURE: Repeated exposure to small doses of Dichlorvos and other organophosphates may lower the cholinesterase to levels where the above symptoms of acute overexposure are observed.
4. FIRST AID MEASURES EYES: Immediately hold eye open and rinse slowly and gently with water for 15-20 minutes. Remove contact lenses, if
present, after the first 5 minutes, then continue rinsing eye. Call a poison control center or doctor for treatment advice.
SKIN: Take off contaminated clothing. Rinse skin immediately with plenty of water for 15-20 minutes. Call a poison
control center or doctor for treatment advice.
INGESTION: If swallowed, IMMEDIATELY call a poison control center or doctor for treatment advice. Do not induce
vomiting unless told to do so by a poison control center or a doctor. Do not give any liquid to the person. Never give anything by mouth to an unconscious person.
Page 1 of 5 INHALATION: Remove affected person to fresh air. If person is not breathing, call 911 or an ambulance, then give artificial
respiration, preferably mouth-to-mouth if possible. Call a poison control center or doctor for further treatment advice.
NOTES TO PHYSICIAN: This is an Organophosphate (OP) Insecticide. Do not wait for laboratory confirmation to
treat patients with strong clinical evidence of poisoning. IV Atropine sulfate is the antidote of choice against parasympathetic nervous stimulation. If there are signs of parasympathetic stimulation , Atropine Sulfate should be injected at 10 minute intervals in doses of 1 to 2 milligrams until complete atropinization has occurred. Pralidoxime chloride (2-PAM chloride) may also be used as an effective antidote in addition to and while maintaining full atropinization. In adults, an initial dose of 1 gram of 2-PAM should be injected, preferably as an infusion, in 250 cc of saline over a 15 to 20 minute period. If this is not practical, 2-PAM may be administered slowly by intravenous injection as a 5% solution in water over not less than 2 minutes. After an hour, a second dose of 1 gram of 2-PAM will be indicated if muscle weakness has not been relieved. For infants and children, the dose of 2-PAM is 0.25 grams. Avoid morphine, aminophylline, phenothiazine, reserpine, furosemide and ethacrynic acid. Clear chest by postural drainage. Oxygen administration may be necessary. Observe patient continuously for 48 hours. Repeated exposure to cholinesterase inhibitors may without warning cause prolonged susceptibility to very small doses of any cholinesterase inhibitor. Allow no further exposure until time for cholinesterase regeneration has been attained as determined by a blood test. Probable mucosal damage may contraindicate the use of gastric lavage.
5. FIRE FIGHTING MEASURES FLASH POINT: 112° F TCC FLAMMABLE LIMITS: LEL: 1.9 UEL: 12.6 EXTINGUISHING MEDIA: Foam, carbon dioxide water fog or dry chemical. HAZARDOUS COMBUSTION PRODUCTS: This product is classified as Non-Combustible, however in the extreme
temperatures that fires may product, some of the constituents of this formula may decompose to give off such gases as carbon monoxide, carbon dioxide, and nitrogen oxides.
EXPLOSION HAZARDS: With sufficient heat or burning, toxic vapors are emitted. Treat as flammable liquid. FIRE FIGHTING PROCEDURES: Treat as an oil fire. Use a full-faced self-contained breathing apparatus along with full
protective gear. Keep nearby containers and equipment cool with a water stream.
SENSITIVITY TO IMPACT: None ACCIDENTAL RELEASE MEASURES SMALL SPILL: Stop release, if possible without risk. Dike or contain release, if possible, and if immediate response can prevent further damage or danger. Isolate and control access to the release area. Take actions to reduce vapors. Absorb with appropriate absorbent. Clean spill area of residues and absorbent. LARGE SPILL: Stop release, if possible without risk. Dike or contain release, if possible, and if immediate response can
prevent further damage or danger. Isolate and control access to the release area. Take actions to reduce vapors. Collect product into drums, etc. via drains, pumps, etc. Absorb with appropriate absorbent. Clean spill area of residues and absorbent.
7. HANDLING AND STORAGE GENERAL PROCEDURES: Do not contaminate water, food or feed by storage or disposal. STORAGE: Store in a secure area preferably under lock and key. Storage area should be equipped to handle an accidental
Page 2 of 5 8. EXPOSURE CONTROLS / PERSONAL PROTECTION EXPOSURE GUIDELINES: OSHA HAZARDOUS COMPONENTS (29 CFR 191 0.1200) EPOSURE LIMITS Chemical Name ACGIH TLV mg/m3 ppm mg/m3 ENGINEERING CONTROLS: Ventilate treatment area thoroughly before re-entry. Use of mechanical or local exhaust PERSONAL PROTECTIVE EQUIPMENT:
Applicators and other Handlers must wear: Coveralls over long sleeved shirt and long pants; Chemical resistant gloves such as Barrier Laminate, Butyl Rubber, Nitrile Rubber, Neoprene Rubber, Polyvinyl Chloride or Viton; Chemical resistant footwear plus socks; Protective Eyewear; Chemical resistant headgear for overhead exposure. RESPIRATORY: Respirator with either an organic vapor removing cartridge with a prefilter approved for pesticides (MSHA/NIOSH approval number TX-23C) or a canister approved for pesticides (MSHA/NIOSH approval number TC-14G or a NIOSH approved respirator with an organic vapor (OV) cartridge or canister with any R, P, or HE prefilter. WORK HYGIENIC PRACTICES: DO NOT SMOKE, EAT, OR DRINK, OR APPLY COSMETICS IN WORK AREA!
Discard clothing and other absorbent materials that have been heavily contaminated with this product. Do not reuse them. Follow manufacturer’s instructions for cleaning and maintaining PPE. If no such instructions for washables, use detergent and hot water. Keep and wash PPE separately from other laundry. Wash promptly if skin becomes contaminated. Wash at the end of each work shift and before eating, drinking, chewing gum, using tobacco, or using the toilet.
9. PHYSICAL AND CHEMICAL PROPERTIES PHYSICAL STATE: Clear Liquid ODOR: Petroleum odor. pH: Not Determined VAPOR PRESSURE: .>1 @ 20° C VAPOR DENSITY: >1 (Air=1) BOILNG POINT: Not Available FREEZING POINT: Not Available SOLUBILITY IN WATER: Insoluble EVAPORATION RATE: Not Available SPECIFIC GRAVITY: 0.81 (Water = 1) at 20°C (68°F) VISCOSITY: 1.37 CPS @ 25° C 10. STABILITY REACTIVITY STABLE: Yes HAZARDOUS POLYMERIZATION: No CONDITIONS TO AVOID: Not compatible with strong acids or bases. Not compatible with strong oxidizers. 11. TOXICOLOGICAL INFORMATION: Acute and chronic toxicity listed below is for Dichlorvos Technical. Oral LD50 (rat): 56 mg/kg Dermal LD50 (rabbit): 205 mg/kg InhalationLC50 (rat): 140 mg/m3 (whole body, mist) Irritation: Skin and Eye irritant Sensitization: Skin (Guinea pig): Possible sensitizer Teratogenicity: No evidence of teratogenicity in laboratory animals.
Page 3 of 5 Mutagenicity: No invivo mutagenicity activity in mammalian assay systems. Carcinogenicity: EPA has classified Dichlorvos as being in Category C, a possible carcinogen. IARC lists Dichlorvos as being possibly carcinogenic to humans (Group 2B). Reproductive Toxicity: Reproductive effects have only been seen at a dose level which produces a generalized toxicity in the rat.
12. ECOLOGICAL INFORMATION ENVIRONMENTAL DATA: Environmental data not available for this product. ECOTOXICOLOGICAL INFORMATION: This product is toxic to aquatic invertebrates, fish, birds and other wildlife. Do not
contaminate water when disposing of equipment wash waters.
13. DISPOSAL CONSIDERATIONS DISPOSAL METHOD: Pesticide wastes are acutely hazardous. If these wastes cannot be disposed of by use according to
label instructions, contact your State Pesticide or Environmental Control Agency, or the Hazardous Waste representative at the nearest EPA Regional Office for guidance.
EMPTY CONTAINER: Nonrefillable container. Do not reuse or refill this container. Triple rinse container (or
equivalent) promptly after emptying. Offer for recycling if available. Triple rinse as follows: Empty the remaining contents into application equipment or mix tank and drain for 10 seconds after the flow begins to drip. Fill container ¼ full with appropriate spray oil and recap. Shake for 10 seconds. Pour rinsate into application equipment or mix tank or store rinsate for later use or disposal. Drain for 10 seconds after the flow begins to drip. Repeat this procedure two more times.
14. TRANSPORT INFORMATION DOT (DEPARTMENT OF TRANSPORTATION) PROPER SHIPPING NAME: HM, ORGANOPHOSPHORUS PESTICIDES, LIQUID, TOXIC, FLAMMABLE, 6.1(3), UN3017, PRIMARY HAZARD CLASS/DIVISION: 6.1 UN/NA NUMBER: UN3017 DOT LABELING: Poison 6, PG III. FLAMMABLE LIQUID 3 AIR (ICAO/IATA) N/A PROPER SHIPPING NAME: N/A PRIMARY HAZARD CLASS/DIVISION: N/A UN/NA NUMBER: N/A VESSEL (IMO/IMDG) PROPER SHIPPING NAME: 15. REGULATORY INFORMATION UNITED STATES SARA TITLE III (SUPERFUND AMENDMENTS AND REAUTHORIZATION ACT) 311/312 HAZARD CATEGORIES: FIRE: No PRESSURE GENERATING: No REACTIVITY: No IMMEDIATE HEALTH HAZARD: Yes DELAYED HEALTH HAZARD: Yes CERCLA REPORTABLE QUANTITIES (RQ): Dichlorvos, CAS# 62-73-7, 10 lbs.; Product: 200 lbs. 302/304 EMERGENCY PLANNING EMERGENCY PLAN: Dichlorvos (DDVP) CAS # 62-73-7 313 TOXIC CHEMICALS: Dichlorvos (DDVP) CAS # 62-73-7 16. OTHER INFORMATION HMIS RATING: 4 – 0 – 0 NFPA RATING: 4 – 0 – 0 HMIS RATINGS NOTES: We assign HMIS ratings to this product based on the hazards of its ingredients(s). Since the
Page 4 of 5
customer is most aware of the applications and conditions of use, he or she must ensure that the proper Personal Protective Equipment is provided, consistent with the information contained in Section's 7 and 8 of this MSDS.
COMMENTS: The data contained herein are based on information currently available to Chem-Tech, Ltd and, to the best of our
knowledge, are accurate and based on sound expert opinion. Our statements herein, however, are not to be taken as a warranty or representation for which the Manufacturer assumes legal responsibility.
Prepared by: Steve Rogosheske, CTL Regulatory Dept.
Page 5 of 5
In an effort to promote the appropriate use of certain drugs and to help better manage the cost of expensive drugs, the ConnectiCare Pharmacy & Therapeutics Committee has developed a list of prescription drugs that require prior authorization. Prior authorization requests must be faxed to ConnectiCare’s Pharmacy Services department at 860-674-2851 or toll free 800-249-1367 by the prescribin
REVISIÓN Efectividad del ejercicio físico como intervención coadyuvante en las adicciones: una revisiónEffectiveness of exercise as a complementary intervention in addictions: a reviewNÚRIA SIÑOL*; ESTER MARTÍNEZ-SÁNCHEZ**; ELISABETH * Unitat de Conductes Addictives, Servei de Psiquiatria, Hospital de la Santa Creu i Sant Pau, Institut d’Investigació Biomèdica Sant Pau (IIB Sant